NRX Pharmaceuticals, Inc.
NRXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001719406
No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in NRX Pharmaceuticals, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +17 vs. Q1 2021
- Shares held
- 1.64M
- +1.64M (+511,739.4%) vs. Q1 2021
- Total value
- $18.9M
- +$18.9M (+473,475.0%) vs. Q1 2021
- New holders
- 17
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NRXP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 47 | $47.6M |
| Q1 2026 | 33 | $13.2M |
| Q4 2025 | 28 | $14.2M |
| Q3 2025 | 24 | $13.0M |
| Q2 2025 | 25 | $9.76M |
| Q1 2025 | 22 | $4.60M |
| Q4 2024 | 25 | $2.31M |
| Q3 2024 | 18 | $1.21M |
| Q2 2024 | 19 | $1.29M |
| Q1 2024 | 31 | $1.76M |
| Q4 2023 | 30 | $1.84M |
| Q3 2023 | 34 | $964.7K |
| Q2 2023 | 32 | $4.78M |
| Q1 2023 | 30 | $2.07M |
| Q4 2022 | 33 | $3.44M |
| Q3 2022 | 30 | $3.04M |
| Q2 2022 | 37 | $2.18M |
| Q1 2022 | 34 | $25.1M |
| Q4 2021 | 38 | $12.4M |
| Q3 2021 | 23 | $16.2M |
| Q2 2021 | 18 | $18.9M |
| Q1 2021 | 1 | $4.00K |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding NRX Pharmaceuticals, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 637,416 | $7.41M | 0.00% | +637,416 | New |
| Linden Advisors LP | 364,352 | $4.23M | 0.02% | +364,352 | New |
| Owl Creek Asset Management, L.P. | 300,000 | $3.40M | 0.16% | +300,000 | New |
| Northern Trust Corp | 130,633 | $1.52M | 0.00% | +130,633 | New |
| HighPoint Advisor Group LLC | 43,501 | $505.0K | 0.05% | +43,501 | New |
| Morgan Stanley | 39,869 | $463.0K | 0.00% | +39,869 | New |
| Ionic Capital Management LLC | 35,721 | $415.0K | 0.05% | +35,721 | New |
| Geode Capital Management, LLC | 34,475 | $400.0K | 0.00% | +34,475 | New |
| Wolverine Asset Management LLC | 19,490 | $226.0K | 0.00% | +19,490 | New |
| Yakira Capital Management, Inc. | 11,923 | $139.0K | 0.02% | +11,923 | New |
| UBS Group AG | 8,385 | $97.0K | 0.00% | +8,385 | New |
| Royal Bank of Canada | 8,000 | $93.0K | 0.00% | +8,000 | New |
| Advisor Group Holdings, Inc. | 3,305 | $38.0K | 0.00% | +3,305 | New |
| CWM, LLC | 320 | $4.00K | 0.00% | 00.0% | Unchanged |
| Deutsche Bank AG | 200 | $2.00K | 0.00% | +200 | New |
| Citigroup Inc | 85 | $1.00K | 0.00% | +85 | New |
| Tower Research Capital LLC (TRC) | 131 | $1.00K | 0.00% | +131 | New |
| Stonebridge Financial Planning Group, LLC | 80 | $1.00K | 0.00% | +80 | New |